GE HealthCare Technologies Inc. GEHC Moat

Key data

The moat

A 500-bed hospital that buys a CT fleet is buying a twelve-year relationship. Leaving means revalidating workflows, retraining technologists and stranding archives. GE HealthCare fields 8,900 field service engineers and 9,700 sales professionals across more than 160 countries, and the service arm also maintains non-GE equipment, so the relationship outlives the hardware decision. That is a switching-cost moat, held with high confidence on the service and consumables layer. Swap in Agilent, Alcon or Cardinal Health and the sentence collapses: none of them sit inside a hospital's imaging workflow with a thousand-engineer field force and an upgradable installed base.

What it produces is price, not volume. FY2024 service revenue grew 3%, or $172 million, which the filing attributes primarily to increased pricing, and Patient Care Solutions grew 8% on price and operational improvements. Record backlog reached $23.9 billion in the June 2026 quarter, up $2.6 billion year over year at a 1.15 times book-to-bill, with roughly three quarters of the sequential build in multiyear service agreements rather than product. Two comparable backlog points only, so treat the level as provisional.

Widening or narrowing

The long sequence argues against the hardware half. Gross margin ran 39.4%, 39.4%, 40.8%, 39.1%, 40.5%, 41.7% and 40.0% from FY2019 to FY2025, a 60 basis point gain across seven years on 24% revenue growth. Operating margin peaked at 15.9% in FY2021 and sat at 13.4% in FY2025. ROIC went 11.6%, 11.3%, 9.6%, 6.8%, 8.3%, 8.8% across FY2020 to FY2025, with the FY2023 trough reflecting the spin-off capital structure rather than operations, and the FY2025 recovery still 280 basis points below FY2020. Revenue per employee moved $367k, $383k, $371k, $382k across four years, which is a flat line.

The fat slice in this chain is the consumable and the recurring contract, and GE HealthCare does hold it. Pharmaceutical Diagnostics grew from $2.31 billion to $2.90 billion in two years, and management cited 14.6% organic growth on volume and pricing in contrast media. The box layer is where the pool is thinnest and where the pressure lands.

The overrated case is simple arithmetic. China revenue fell from $2.56 billion to $2.13 billion to $2.03 billion across FY2023 to FY2025, a 21% decline over two years, while United Imaging grew 2025 revenue 33.98% to RMB 13.80 billion and lifted domestic share 1.7 points. GE HealthCare's capital franchise is losing ground in the world's second-largest imaging market while its aggregate returns sit below 2020 levels. Narrowing.

What breaks it, and who

Value-based procurement and provincial budget pressure in China are the live wound. A domestic challenger that wins the new tender wins the next decade of service revenue on that site, and United Imaging has already installed more than 640 high-end systems with coverage in over 90% of US states.

Generic contrast media is the second pressure. Management said generic competition "is not new in these contrast media markets," which is a claim, not evidence; PDx growth is currently proving the opposite, and the test is whether pricing holds past patent and exclusivity windows.

The read changes on three items in the next 12 to 18 months: whether backlog conversion lifts PCS margin as promised, whether China revenue stops declining, and whether PDx pricing holds as generic entrants scale.

Closing thoughts

The moat is real and conditional, and it is narrowing. The service and consumables annuity is the durable part, evidenced by priced service growth and a backlog where most of the recent build is multiyear contracts, and the hardware franchise is the eroding part, evidenced by a flat seven-year gross margin, ROIC still below FY2020, and two straight years of China decline against a domestic rival compounding above 30%. The one checkable thing is recurring revenue as a disclosed share of total, which is not in the filings reviewed as a sequence; absent that, China revenue and PDx price-volume split are the usable proxies. The moat strengthens if service and consumables revenue grows faster than product revenue for four straight quarters while China revenue stabilizes, and weakens if China declines a third year and PDx pricing turns negative on generic entry.